CPAP Effect on Albuminuria in Patients With Diabetic Nephropathy and Obstructive Sleep Apnea

Phase 4

Completed

• Conditions: Diabetic Nephropathy; Sleep Apnea
• Interventions: Device: Continuous positive airway pressure; Drug: Pharmacological treatment; Other: Diet

• Registration Number: NCT02816762
• Lead Sponsor: Hospital Universitario La Paz

Brief Summary

Objectives: Main objective: To assess the effect of 12 months of CPAP treatment added to conventional drug treatment on the albuminuria in patients with diabetic nephropathy and obstructive sleep apnea (OSA). Secondary objectives: To evaluate the effect of CPAP treatment on the estimated glomerular filtration rate of patients with diabetic nephropathy and OSA; determine the additional longterm CPAP effect on glycemic control, insulin resistance, lipid profile, health-related quality of life and biomarkers of cardiac function, inflammation, oxidative stress, sympathetic tone and appetite-regulating hormones in patients with diabetic nephropathy and OSA; and to identify the subgroup of patients with diabetic nephropathy and OSA in which 12 months of treatment with CPAP achieve a more pronounced reduction in albuminuria.

Methodology: Randomized, multicenter, non-blinded, parallel groups, conventional treatment-controlled trial of 12 months of duration.

Subjects will randomize to conventional dietary and pharmacological treatment or conventional dietary and pharmacological treatment plus continuous positive airway pressure (CPAP). Study subjects: Subjects 18 to 80 years with overweight or obesity and a clinical diagnosis of diabetic nephropathy, increased urinary albumin/creatinine ratio of 30 mg/g and an estimated glomerular filtration rate \>20 ml/min/1.73 m2, and treatment with stable doses of angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs) or anti-aldosterone drugs in the last four weeks. Efficacy variables:

urinary albumin/creatinine ratio and estimated glomerular filtration rate; glycosylated hemoglobin (HbA1c); fasting glucose and insulin; homeostatic model assessment (HOMA) and QUICKI indices; total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides; Troponin I, proBNP, homocysteine and high-sensitivity C-reactive protein; systemic biomarkers (inflammation \[IL-6, IL-8 and tumor necrosis factor-α\], oxidative stress \[8-isoprostane\], endothelial damage \[endothelin, VCAM-1 and ICAM-1\], sympathetic activity \[neuropeptide Y\] and appetite-regulating hormones \[leptin and adiponectin\]) and clinical questionnaires: short form (SF)-12, EuroQoL and iPAQ.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2016-05-31
• Study Start: 2016-06
• Study First Submitted QC: 2016-06-24
• Study First Posted: 2016-06-29
• Primary Completion: 2020-12
• Study Completion: 2020-12
• Status Verified: 2021-05
• Last Update Submitted: 2021-05-10
• Last Update Posted: 2021-05-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 180

Inclusion Criteria

• Subjects aged 18 to 80 years old
• Overweight or obesity (BMI ≥25 kg/m2)
• Previous diagnosis of type 2 diabetes, fulfilling at least one of the following criteria: 1) current treatment with oral antidiabetic drugs and/or insulin; 2) a fasting glucose value above 126 mg/dl on at least 2 occasions; 3) blood glucose level at 2 hours after an oral glucose tolerance test is equal to or more than 200 mg/dl; or 4) a glycated hemoglobin (HbA1c) level > 6.5 %
• Clinical diagnosis of diabetic nephropathy, with a urinary albumin/creatinine ratio >30 mg/g and an estimated glomerular filtration rate more than 20 ml/min per 1.73 m2.
• Treatment with stable doses of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers or anti-aldosterone agents in the last four weeks.

Read More

Exclusion Criteria

• Non diabetic nephropathy (confirmed by biopsy).
• Dialysis for acute renal failure within the 6 previous months.
• Evidence in the clinic history of relevant bilateral stenosis of renal artery (> 75%)
• Urinary albumin/creatinine ratio higher than 3000 mg/g, at the baseline visit.
• Systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mm Hg at the baseline visit.
• Stroke, transient ischemic attack, acute coronary syndrome, or hospitalization for heart failure worsening, within the previous 30 days.
• Professional drivers, risk profession or respiratory failure.
• Severe daytime sleepiness (Epworth sleepiness scale >18)
• Concomitant treatment with high doses of acetylsalicylic acid (> 500 mg/day) or continuous treatment with non-steroidal anti-inflammatory drugs
• Previous treatment with CPAP
• Participation in another clinical trial within the 30 days prior to randomization.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
CPAP treatment	Continuous positive airway pressure	Diet and conventional pharmacological treatment with angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists or anti-aldosterone agents plus continuous positive airway pressure (CPAP)
CPAP treatment	Pharmacological treatment	Diet and conventional pharmacological treatment with angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists or anti-aldosterone agents plus continuous positive airway pressure (CPAP)
CPAP treatment	Diet	Diet and conventional pharmacological treatment with angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists or anti-aldosterone agents plus continuous positive airway pressure (CPAP)
Control treatment	Pharmacological treatment	Diet and conventional pharmacological treatment with angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists or anti-aldosterone agents.
Control treatment	Diet	Diet and conventional pharmacological treatment with angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists or anti-aldosterone agents.

Primary Outcome Measures

Name	Time	Method
Change form baseline in albuminuria levels	12 months	To compare the change in albuminuria levels between the patients allocated to CPAP group and the control group

Secondary Outcome Measures

Name	Time	Method
Change form baseline in the plasmatic levels of 8-isoprostane	12 months	To compare the change in the plasmatic levels of 8-isoprostane between the CPAP group and the control group
To identify the CPAP-responder subgroup of OSA patients with diabetic nephropathy	12 months	To identify the subgroup of OSA patients with diabetic nephropathy in those the CPAP treatment achieve an albuminuria reduction \>20% from baseline.
Change from baseline in glycated hemoglobin levels	12 months	To compare the change in glycated hemoglobin levels between the patients allocated to CPAP group and the control group
Change from baseline in the daily physical activity of patients with diabetic nephropathy and OSA	12 months	To compare the change in the total score of the International Physical Activity Questionnaire (iPAQ) between the CPAP group and the control group
Change form baseline in the plasmatic levels of endothelin	12 months	To compare the change in the plasmatic levels of endothelin, intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) between the CPAP group and the control group
Change from baseline in the health-related quality of life assessed by the SF-12 questionnaire	12 months	To compare the change in the total score and the domains of the questionnaire SF-12 between the CPAP group and the control group
Change from baseline in the health-related quality of life assessed by the EuroQoL questionnaire	12 months	To compare the change in the total score and the domains of the questionnaire EuroQoL between the CPAP group and the control group
Change form baseline in HOMA index	12 months	To compare the change in HOMA index between the patients allocated to CPAP group and the control group
Change form baseline in QUICKI index	12 months	To compare the change in QUICKI index between the patients allocated to CPAP group and the control group
Change from baseline in cholesterol levels	12 months	To compare the change in the levels of total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides between the patients allocated to CPAP group and the control group
Change from baseline in the levels of C-reactive protein	12 months	To compare the change in the levels of C-reactive protein between the patients allocated to CPAP group and the control group
Change form baseline in the plasmatic levels of biomarkers of inflammation	12 months	To compare the change in the plasmatic levels of interleukin (IL)-1beta, IL-6, IL-8 and tumor necrosis factor-alpha between the CPAP group and the control group
Change form baseline in the plasmatic levels of appetite-regulating hormones	12 months	To compare the change in the plasmatic levels of leptin and adiponectin between the CPAP group and the control group

Trial Locations

Locations (6)

Hospital Universitari Son Espases; 🇪🇸 Palma de Mallorca, Islas Baleares, Spain

Hospital Universitario General de Guadalajara; 🇪🇸 Guadalajara, Spain

Hosptial Universitario La Paz, IdiPAZ; 🇪🇸 Madrid, Spain

Hospital Universitario Infanta Sofía; 🇪🇸 San Sebastián de los Reyes, Madrid, Spain

Fundación Jiménez Díaz; 🇪🇸 Madrid, Spain

Hospital Universitario 12 de Octubre; 🇪🇸 Madrid, Spain